Fig 1A: PPV only (n = 5) Staging EUA Enucleation Systemic chemotherapy

Slides:

Advertisements

Similar presentations

TA OGUNLESI (FWACP)1 RETINOBLASTOMA. 2 RETINOBLASTOMA It is the most common primary ocular malignancy of childhood. It formed 15% of all childhood cancers.

Advertisements

What is the treatment?. For the Patient Chemotherapy- initial Enucleation- if unsuccessful.

« A Clear cell sarcoma » FN. 25 year-old male January cm mass on the medial side of the right heel Early August cm clinical right.

ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Boston Type I Keratoprosthesis and Silicone Oil for the Treatment of Hypotony in Prephthisis Kristiana D. Neff 1, William I. Sawyer 2, Michael R. Petersen.

Diabetes and Your Eyes.

Clinical Research in a Community Practice Bob Behrens, MD Iowa Oncology Research Association (IORA)

Clinical and Visual Outcomes of Children With Peters Anomaly Asim Ali, MD, FRCSC Uri Elbaz, MD Hermina Strungaru, MD, PhD Kamiar Mireskandari, MBChB, FRCSEd,

AlphaCor TM : A Novel Approach to Minimize Late Post-operative Complications V. Ngakeng MD, M. Price PhD. MBA, F. Price MD.

Treatment of Eye Cancer in Children With Chemosurgery Pierre Gobin (1), David Abramson (2), Ira Dunkel (3) 1: Interventional Neuroradiology, Weill Cornell.

Cancer Accelerated Biology. Learning Objectives The different methods of diagnosing cancer. The difference between a malignant tumor and a benign tumor.

Ocular Candidiasis Rupesh Agrawal, Carlos Pavesio Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.

GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.

 To explain the main methods of examination of an eye,  to show the methods that should be performed by general practitioner,  to know how to write.

Classic Lattice Degeneration. Perivascular Lattice.

Corneal vs. Scleral Incisions: Managing Lens luxation in homocystinuria Suqin Guo, MD,* Tatyana Milman, MD, N Bhagat, MD, D Chu, MD and R Fechtner, MD.

Bellringer  What does the word cancer make you think of?

Case 3 75 Yr male. pT1 TCC upper ureter. Smoker CKD stage 2 Diabetic Monday morning. Patient admitted for lap nephroureterectomy. Discuss procedure and.

Age-Related Eye Diseases You Should Be Tested For.

Kuo-Hu Chen, Li-Ru Chen Taiwanese Journal of Obstetrics and Gynecology

Refractive Anomalies.

SYMPATHETIC OPHTHALMIA: EXPERIENCE IN A TERTIARY REFERRAL CENTER

The Diabetic Retinopathy Clinical Research Network

Characteristics of a pediatric low vision population in Italy E

Outline for Lab 4 Vessels Identification in torsos, arms, & legs and break. Student-led learning Order doesn’t matter Arms and legs are less abundant Notes.

Why don’t we achieve expected outcome in vitreoretinal surgery

DEPARTMENT OF COUNSELLING

State of the art treatments in diabetic eye disease

Surgical treatment of hepatic and pulmonary metastases from colon cancer James R Headrick, MD, Daniel L Miller, MD, David M Nagorney, MD, Mark S Allen,

From: Effect of Cataract Surgery on Optical Coherence Tomography Measurements and Repeatability in Patients With Non-Insulin–Dependent Diabetes Mellitus.

Modified Osteo-Odonto Keratoprosthesis (MOOKP) in patients with severe anterior segment disease: Our Hong Kong Experience Bone – Tooth Cornea replacement.

YOUR ACTIONS PROTECT ANTIBIOTICS, RALLY TOGETHER AT

Consort Diagram 600 pts with 644 eyes accessed for eligibility

DIABETES AND THE EYE.

This talk will follow the topical structure suggested by the ABP:

Sight Loss and Vision Priority Setting Partnership

Consort Diagram 600 pts with 644 eyes accessed for eligibility

SORVEGLIANZA ATTIVA DELLE PICCOLE MASSE RENALI

RETINOBLASTOMA By: Kristin Gartman Kristen Ryan Mario Cotton.

Sarcoma Wound Complications

NeuroScience and Service

Allan B. Dunlap, MD, Gregory S. Kosmorsky, DO, Vikram S. Kashyap, MD

!'!!. = pt >pt > \ ___,..___,..

Ophthalmology Procedures

Task 1 Discriminate between sensation and perception.

Chapter 7 Strategic decision making

A presentation to: Meeting name Date

A Figure 1. (A) Left, RetCam fundus photograph of child 1 showing a right multilobulated tumor with overlying serous retinal detachment (RD) and subretinal.

Traumatic Wound Dehiscence After Corneal Keratoplasty

Surgical treatment of hepatic and pulmonary metastases from colon cancer James R Headrick, MD, Daniel L Miller, MD, David M Nagorney, MD, Mark S Allen,

Notes: Regulating the Cell Cycle

Assessed for eligibility (N = 600)

Diseases of the Eyes.

BACTERIAL AND FUNGAL ENDOPHTHALMITIS AFTER PENETRATING KERATOPLASTY

Long-Term Survival After Coronary Arterial Grafts in Patients With End-Stage Renal Disease Taro Nakatsu, MD, Nobushige Tamura, MD, PhD, Yutaka Sakakibara,

Studied for effect of delayed enucleation on mortality

Camryn Schulz Luxation:

A B C D E Biopsy (incisional) Biopsy (excisional)

Retinoblastoma Treated by Chemotherapy and PPV with 5 Years Follow-up

Consort Diagram 600 pts with 644 eyes accessed for eligibility

Patients Excluded from Study

A I II 1 2 H1 H0 20/ logMAR B F+F C D Figure 1. (A) Pedigree of a family with a unilaterally affected father discovered to be mosaic (H1) for a high.

Studied for effect of delayed enucleation on mortality

DePICTrb Database corrections October 2017

DePICTrb Database corrections October 2017

Studied for effect of delayed enucleation on mortality

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Presentation transcript:

Fig 1A: PPV only (n = 5) Staging EUA Enucleation Systemic chemotherapy PPV iVit Melphalan Intra-arterial Chemotherapy Death Silicon oil removal Pathology Last Follow-up Retinal detachment surgery Cataract surgery cT3d/E cT2b/D #32 6.1 1 2 3 4 5 3.3 20/60 #99 4.0 cT2b/D 3.0 1 2 3 20/60 ?/? cT2b/D 6 #84 6.6 3.1 1 2 3 4 5 20/200 1 2 3 #42 4.9 3.2 4 cT3d/E cT2b/D CF pT1 7 PPV only Explain #41 why chemo after Explain #77 why delay to start treatment from november to march; no chemo?? Or elsewhere? Stage B at diagnosis? 7.7 1 2 3 4 5 6 7 #60 cT2a/C cT2b/D 3.1 CF pT2b Fig 1B: PPV followed by systemic chemotherapy (for the enucleated eye) (n = 2) 3 #77 3.6 3.0 1 2 cT3a/E cT1b/B 20/40 pT3b 1 4 4.2 #41 3.2 cT2b/E cT2b/D 2 3 20/100 20/60 pT3b

Fig 1C: PPV followed by Intravitreal Melphalan (n = 10) 20/40 #40 4.1 1 2 3 ?/E cT2b/C 3.3 4 2 3 4.3 1 #25 3.4 cT3c/E cT2b/D pT1 20/50 #27 cT3c/E cT2b/D 4.1 3.3 1 2 3 20/50 pT2a #28 cT2a/D cT3c/E 3.3 1 2 3 4.0 20/50 4 #74 cT2b/E cT2b/D 4.3 1 2 3 3.0 20/60 pT1 9 PPV + IVitC #26 1 3.3 cT3c/E cT2b/D 3.6 2 pT2a 3 20/80 cT2b/D #34 cT2a/C 9.8 1 2 3 4 5 6 7 8 9 3.3 pT2a 20/100 #108 cT2b/E cT2b/D 4.8 4 2 3 1 2.9 CF pT1 #37 2.8 1 2 cT2b/E cT2b/D 2.3 LP 5.3 1 2 4 #29 5 ?/? 3 cT2b/D 3.3 LP

Fig 1D: Failure, PPV followed by enucleation (2), or repeat PPV (2) with 1 lost to follow-up (n = 4) 3 4 #24 cT3c/E cT2b/D 3.3 NLP 4.3 pT1 #44 cT2b/D 5.4 1 2 3 4 5 1.9 NLP pT2a #94 3.0 (2.0) cT2b/E cT2b/D 5.8 1 2 3 4 5 20/100 pT2a #65 cT3b/E cT2b/D 1 2 3 1.6 3.4 (LTF) ? pT2a 5 failures after PPV #94 recurrence one year later; repeat PPV #29 repair retinal detachment #37 also retinal detachmnet

Included (n = 21) Bilateral, Last Eye Enucleated (n = 2, 10% ) Eye Assessable (n = 20) Lost to Follow-up (LTF) (n = 1) Metastasis / Death (n = 0) Vision Not blind (n = 12, 67%) >20/80 (n = 10) 20/100 to 20/200 (n = 2) Functional (n = 5, 28%) Light perception (n = 1, 6%) Post PPV Rx None (n = 5) CEV for other eye high risk path (n = 2) IVitC, x 1-4 (n = 10) Repeat PPV (n = 1) Saved (n = 18, 90% )